EMEA-002551-PIP01-18

Key facts

Active substance
capivasertib
Therapeutic area
Oncology
Decision number
P/0214/2019
PIP number
EMEA-002551-PIP01-18
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
  • Treatment of breast cancer
  • Treatment of prostate cancer
Route(s) of administration
Oral use
Contact for public enquiries
AstraZeneca AB (UK)

Tel.: +44 7384522139
E-mail: lee.anderson2@astrazeneca.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating